Trial Profile
An open-label, clinical pharmacology study to evaluate the safety and PK [pharmacokinetics] of MRA [tocilizumab] in patients with RA [rheumatoid arthritis] with renal impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 14 Dec 2008 Actual end date March 2006 changed to October 2005 as reported by CT.gov
- 13 Aug 2007 Status changed from in progress to completed.
- 04 Dec 2005 New trial record.